Browse studies

Find your next paid study

5 recruiting studies matching your filters

MC230719 Window Of Opportunity Study Of GI-102 In Patients With Recurrent High-Grade Glioblastoma

This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype gliob…

Glioblastoma, IDH-WildtypeProgressive Astrocytoma, IDH-Mutant, Grade 4Progressive Glioblastoma+6 more

Estimated

~$10 – $6,250

Mayo ClinicNCT07301268

Phase 1

Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurren…

IDH1 wt AlleleRecurrent Anaplastic AstrocytomaRecurrent Glioblastoma+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT03896568

Phase 1

A Phase Ib Open Label Clinical Trial to Evaluate the Safety and Efficacy of ERAS-801 in Recurrent Glioblastoma or Elderly Newly Diagnosed Glioblastoma Patients With EGFR Amplification and/or Mutation (ERAS-801-3.0)

This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor re…

GlioblastomaGlioblastoma, IDH-WildtypeGliosarcoma+3 more

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT07089641

Phase 1

A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Grade 4 Astrocytoma (Glioblastoma)

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 an…

Recurrent GliosarcomaRecurrent Supratentorial GlioblastomaSupratentorial Gliosarcoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04991870

Phase 2

Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurren…

High Grade Astrocytic TumorRecurrent Glioblastoma, IDH-WildtypeRecurrent Gliosarcoma

Estimated

~$10 – $6,250

Mayo ClinicNCT05465954